<unk> , trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and Uzbekistan.<unk>  employs technology similar to other protein-based vaccines in Phase III trials from Novavax, Vector Institute, and Medicago.<unk>  was first approved for use in Uzbekistan and later China. Production capacity is expected to be one billion doses a year in China and 200 million in Uzbekistan. By July, 100 million doses had been administered in China and Uzbekistan.
ZF2001
DEBRA
HAMLET 
ACDC 
CoWIN
MIS416
ESKAPE
ABL 